-

Applaud Medical Changes Name to Avvio Medical, Ushering in a New Era of Kidney Stone Treatment

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc. (formerly Applaud Medical), a company dedicated to revolutionizing the treatment of urinary stones, today announced a bold step forward with a new name that reflects the Company’s vision for the future.

"Avvio is more than just a new name," stated Paul Molloy, President and Chief Executive Officer of Avvio Medical. "Meaning ‘start’, Avvio embodies the company’s unwavering dedication to propelling the future of kidney stone treatment. This name change signifies our commitment to bringing a novel technology, the AVVIO Acoustic Cavitation Lithotripsy System, to market and transforming the patient experience."

The AVVIO Acoustic Cavitation Lithotripsy System: A Paradigm Shift on the Horizon

The AVVIO Acoustic Cavitation Lithotripsy System utilizes low-pressure ultrasound waves to target patented AVVIO Microbubbles. The expansion and collapse of these microbubbles gently fragment urinary stones, offering an efficient, minimally invasive solution with the potential to:

  • Eliminate the need for anesthesia and X-ray imaging in many cases
  • Significantly expand treatment access, driving greater health equity
  • Provide a more convenient and potentially less stressful experience for patients

About Avvio Medical

Avvio Medical is a privately held company which aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of urinary stones. The company’s initial technology is designed to offer patients and healthcare professionals a fast, minimally invasive solution for treating urinary stone disease in various clinical or outpatient settings, eliminating the routine need for anesthesia or X-ray imaging.

For more information, visit www.avviomed.com/

Contacts

Paul Molloy
Chief Executive Officer
Avvio Medical, Inc.
Email: paul.molloy@avviomed.com
Tel: (415) 887-2037

Avvio Medical


Release Versions

Contacts

Paul Molloy
Chief Executive Officer
Avvio Medical, Inc.
Email: paul.molloy@avviomed.com
Tel: (415) 887-2037

More News From Avvio Medical

Avvio Medical Proudly Announces ISO 13485 Certification, Marking a Major Milestone in Global MedTech Readiness

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a clinical-stage medical device company focused on transforming the treatment of kidney stone disease, is proud to announce that it has successfully achieved ISO 13485:2016 certification following its initial audit conducted by BSI (British Standards Institution). This globally recognized certification demonstrates Avvio’s compliance with international standards for medical device quality management systems and reflects the company’s unwaveri...

Avvio Medical Announces First Patients Treated with Groundbreaking Kidney Stone Therapy

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc. (formerly Applaud Medical, Inc.) today announced the successful treatment of the first patients using its investigational Enhanced Lithotripsy System (ELS), a pioneering advancement in kidney stone therapy. This milestone follows the company’s recent approval of its Investigational Device Exemption (IDE) by the U.S. Food and Drug Administration (FDA), marking the official launch of its clinical trial. “Our team has developed a world-class solu...

Avvio Medical to Present Clinical Trial Results at the 2025 American Urological Association Annual Meeting

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical Inc. (formerly Applaud Medical, Inc.) today announced that results from its AEROLITH randomized clinical trial will be presented at the upcoming 2025 American Urological Association (AUA) Annual Meeting, taking place April 26-29 in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones....
Back to Newsroom